Table 3. PA-Specific Endpoint Titers and LF Neutralizing Activity.
| A | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 2nd immunization | 3rd immunization | ||||||||
| Sample | Dose (μg) | Endpoint* | Neutralizing† | Endpoint | Neutralizing | ||||
| DNI T 0 |
10 | 29 407 | 200 | 612 066 | 1600 | ||||
| 1 | 4222 | 1 | 128 000 | 528 | |||||
| DNI 2 w, 40 °C |
10 | 29 407 | 230 | 443 613 | 2786 | ||||
| 1 | 5572 | 8 | 128 000 | 528 | |||||
| DNI 2 w, 70 °C |
10 | 51 200 | 264 | 844 485 | 1838 | ||||
| 1 | 3676 | 53 | 84 449 | 606 | |||||
| DNI 4 w, 40 °C |
10 | 44 572 | 230 | 703 079 | 3200 | ||||
| 1 | 4222 | 18 | 194 012 | 606 | |||||
| DNI 4 w, 70 °C |
10 | 51 200 | 53 | 559 801 | 1600 | ||||
| 1 | 12 800 | 132 | 256 000 | 800 | |||||
| B | |||||||||
| 2nd immunization | 3rd immunization | ||||||||
| Sample | Dose (μg) | Endpoint* | Neutralizing† | Endpoint | Neutralizing | ||||
| DNI control | 10 | 9406 | 72 | 258 032 | 3200 | ||||
| 1 | 3456 | 8 | 87 782 | 1176 | |||||
| rPA control | 10 | 47 405 | 741 | 278 690 | 4355 | ||||
| 1 | 10 159 | 62 | 110 598 | 1728 | |||||
*
values are the geometric mean of five samples. †Lowest dilution tested, 1:100. Samples with no detectable neutralizing titers were set to 1 for the sake of calculating geometric means.